Solving The Silicone Challenge In Pre-Fillable Syringes

The pre-filled syringes market is experiencing rapid growth, driven by factors such as the rise of biologics, biosimilar drugs, self-administration, and chronic illnesses. It is projected that healthcare spending on drugs delivered through pre-filled syringes will exceed $300 billion by 2027. However, the use of silicone in these syringes can lead to the release of subvisible particles, causing injection irregularities and reducing drug concentration.

To combat this issue, Stevanato Group has developed the Alba® platform, which utilizes a plasma treatment on silicone coating to create a barrier that improves stability and resistance to breakdown. The platform underwent extensive testing, including thickness analysis, extrusion force testing, and subvisible particle analysis. The results showed that the Alba® syringes outperformed silicone oil syringes in terms of subvisible particle release, coating stability, and reliability.

Stevanato Group's Alba® platform is a transformative advancement that addresses the challenges of silicone sensitivity in pre-fillable syringes. With its superior performance and stability, it offers a reliable and efficient packaging solution for sensitive drug products, saving costs and improving patient care.

Learn more about a technology platform that is revolutionizing the pre-fillable syringe market by solving the challenge of silicone sensitivity. This breakthrough solution ensures stability for sensitive drugs, addressing the growing demand for high-performance containers in the pharmaceutical industry.